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Abstract
Translocations involving the Mixed Lineage Leukemia (MLL) gene generate in-frame fusions of MLL with more than 50
different partner genes (PGs). Common to all MLL translocations is the exchange not only of coding regions, but also of MLL
and PG 39-untranslated regions (39UTRs). As a result, the MLL-PG fusion is normally highly expressed and considered the
main driver of leukemia development, whereas the function of the PG-MLL fusions in leukemic disease is unclear. As 39UTRs
have been recognized as determinant regions for regulation of gene expression, we hypothesized that loss of the MLL
39UTR could have a role in generating high MLL-PG levels and leukemia development. Here, we first tested the MLL-PG and
PG-MLL mRNA levels in different leukemic cells and tumours and uncovered differential expression that indicates strong
repression by the MLL-39UTR. Reporter assays confirmed that the 39UTR of MLL, but not of its main PGs, harbours a region
that imposes a strong gene silencing effect. Gene suppression by the MLL 39UTR was largely microRNA independent and
did not affect mRNA stability, but inhibited transcription. This effect can at least partially be attributed to a tighter
interaction of the MLL 39UTR with RNA polymerase II than PG 39UTRs, affecting its phosphorylation state. Altogether, our
findings indicate that MLL translocations relieve oncogenic MLL-PG fusions from the repressive MLL 39UTR, contributing to
higher activity of these genes and leukaemia development.
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Introduction
The mixed lineage leukemia (MLL) proto-oncongene is a
recurrent site of genomic rearrangements in acute myeloid
leukemias (AML) [1]. Uniquely, MLL is rearranged with more
than 50 different partner genes (PGs), all involving the in-
frame fusion of MLL 59- t e r m i n a lp a r tt oP G( M L L - P G )a n da
reciprocal fusion of PG to MLL 39-terminal part (PG-MLL)
[1,2] (Fig. 1A).
Since the discovery of MLL in 1992 [3], many advances have
been made in understanding its role in leukemia [1,4,5,6]. Five
MLL translocations account for approximately 80% of MLL
rearrangements: MLL-AF4 [t(4;11)(q21;q23)], MLL-AF6 [t(6;11)
(q27;q23)], MLL-AF9 [t(9;11)(p22;q23)], MLL-ELL [t(11;19)
(q23;p13.1)] and MLL-ENL [t(11;19)(q23;p13.3)] [7,8], although
more than 70 different translocations have been identified [8].
Intriguingly, all translocations involving MLL generate two
common different events: a gain of function (MLL-PG), which is
normally highly expressed, and haplo-insufficiency for wild-type
MLL [4,9]. Furthermore, current evidence indicates that forma-
tion of dimers of MLL N-terminal domains might be important for
leukemogenesis [10], and this could be favoured after MLL
translocation and MLL-PG overexpression. Certainly, as all MLL-
PG fusions, regardless of the PG, exhibit a distinct gene expression
signature and induce acute leukemia development [2,11], the
MLL-PG overexpression and dimerization may play a role.
39UTRs have been recognized as major regulatory regions in
genes [12,13]. They can mediate gene regulation mainly at the
level of translation and mRNA stability by providing docking sites
for microRNAs [13,14] and RNA binding proteins [15]. Changes
in 39UTR length, sequence or location can influence gene
expression, cell proliferation and survival and lead to cancer
development. For instance, translocations affecting the oncogene
HMGA2 swap its 39UTR for that of another gene resulting in loss
of the let-7 miRNA target sites, escaping from miRNA-mediated
gene repression and leading to HMGA2 overexpression and
tumorigenesis [16]. Moreover, many genes contain proximal and
distal polyadenylation signals (PASs) in their 39UTRs, that when
aberrantly activated will lead to shortening of the 39UTR and
escape of miRNAs or RBPs repression as found in cyclin D1 and
D2 [12]. Nonetheless, apart from 39UTR shortening, transloca-
tion or PAS mutation, other 39UTR-mediated gene expression
control mechanisms at the RNA level may exist and still remain to
be identified.
Here, we have investigated the role of MLL-39UTR in
restricting MLL expression. Our results suggest that by exchang-
ing 39UTRs, MLL-PG translocations evade a strong transcrip-
tional gene repressive control mediated by the 39UTR of MLL
which leads to MLL-PG overexpression and leukemogenesis.
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MLL translocations generate two different chimeric genes: MLL-
PG and PG-MLL (Fig. 1A). To address if MLL-PG and PG-MLL
expression differ at the mRNA level, we designed two different pair of
primers (Fig. 1B). The 59pair measures wt MLL and MLL-PG
mRNA levels while the 39pair measures wt MLL and PG-MLL
mRNA levels. In the absence of MLL translocation, equal mRNA
levels must be found for both 59 and 39pair primers. Indeed, the cell
lines HL-60 and U2OS that are known to have wild-type (wt) MLL
and the EOL cell line, which contains partial tandem duplication
(MLL-PTD), showed no difference between both primer pairs
quantification (Fig. 1B). We therefore used these cell lines to
normalize MLL expression in the leukemic cell lines with MLL
translocations. We expected that if the translocations affected the
relative abundance of MLL-PG mRNA with regard to PG-MLL, an
inverse change in the level of mRNA detected by the 59pair and the
39 pair should be observed in cell lines harboring MLL rearrange-
ments. Intriguingly, all cell lines with MLL-AF9 and MLL-AF6
translocations showed a relatively higher expression of mRNA
detected by the 59 pair, while a marked reduction by the 39pair
(Fig. 1B). Only the cell line MV4-11 with an MLL-AF4 translocation
showed similar 59 and 39 mRNA expression (Fig. 1B), suggesting that
in this case no relative change in expression was induced by the
Figure 1. Expression pattern of MLL-PG and PG-MLL in leukemogenic cell lines and tumors. A, A schematic representation of MLL
translocations with a partner gene (PG) at the mRNA level. AT hooks are designated (AT hooks domain); NLS (Nuclear Localization Signal); RDs
(Repressor domains); PHDs (Plant homology domains); TA (Taspase domains); SET (methyl-transferase domain). B, RT-qPCR analyses, with 59and
39pair primers, as depicted, to detect MLL, were performed with RNA extracted from several cell lines, as indicated. The status of MLL is annotated
and summarized in Supplementary Table S1. C, MLL mRNA quantification using the same primer sets as above of RNA extracted from leukemogenic
patient samples with or without MLL-translocations. The status of MLL is annotated and summarized in Supplementary Table S2. Patients mRNA
levels expression was evaluated individually but statistically analized as pulls regarding MLL status. D, RT-qPCR to quantify AF-9 mRNA levels by using
the indicated 39 and 59 primers in cell lines harboring MLL translocations as indicated. The status of MLL is annotated and summarized in
Supplementary Table S1.
doi:10.1371/journal.pone.0025449.g001
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performed q-RT-PCR quantification of 59 and 39MLL expression in
AML patient samples. The type of translocation was determined by
FISH analysis (see methods). A consistent pattern to the cell lines was
revealed: patients with no MLL translocations showed no difference
in 59 and 39 detection primers, patients harboring MLL-PG
translocations (excluding MLL-AF4) presented a higher 59MLL
expression, pointing to a higher MLL-PG expression in relation to
PG-MLL mRNA levels, and patients with MLL-AF4 translocation
showed no statically significant differences in mRNA levels between
both primer pairs (Fig. 1C). All together, these results demonstrate
that MLL translocations, with the exception of AF4, lead to higher
levels MLL-PG and inhibition of PG-MLL expression.
The change in relative PG-MLL expression observed upon
translocation could be explained by low activity of PG promoter,
or by repression inflicted by MLL 39UTR region, or both. To
distinguish between these possibilities we measured the expression
of PG-AF9 in MLL-AF9 cell lines using 59 and 39 PCR primer
pair sets designed in the same way we did for MLL mRNA levels
(Fig. 1D). We used ML-2 cell line (harboring an MLL-AF6
translocation) to normalize the data. First, both primer sets
identified consistent AF9 mRNA expression in all cell lines with wt
AF9, indicating that AF-9 promoter is active (data not shown).
Second, in all the cell lines with MLL-AF9 translocations a
relatively higher expression level of 39 AF9 mRNA (MLL-AF9)
was observed, accompanied with either a reduction, or no change,
in 59-AF9 (AF9-MLL) expression (Fig. 1D). This antagonistic
pattern of change in expression for both MLL and AF9 in MLL-
AF9 translocations excludes the possibility of AF9-MLL silencing
due to AF9 low promoter activity, while pinpointing an active
repression of AF9-MLL expression by MLL’s 39 region.
To examine whether the MLL-39UTR can potently suppress
gene expression (Fig. 2A) we cloned it downstream of the Renilla
luciferase reporter gene in the psiCheck2 (Y2) dual reporter vector
(where Renilla luciferase and control Firefly luciferase are expressed
from the same vector) (Fig. S1A), and downstream of the Firefly
luciferase gene in the pGL3 vector. In both cases, strong repression
(,10 folds) was mediated by MLL-39UTR (Fig. 2B). This
suppression was seen in all cell lines tested thus far (Fig. 2C),
regardless of their tissue of origin, including HL-60 and Jurkat
leukemic cell lines (Fig. 2D), and was also observed when examining
the 39UTR of mouse MLL (Fig. S1B). Most interestingly, the main
PGs-39UTRs [8] had only a mild gene reporter suppressive effect or
no effect at all, when analyzed in different cell lines (Figs. 2D and
S1C). As MLL-39UTR length is not significantly different from that
of its PGs (Fig. 2D), we suggest that MLL-39UTR could possess
strong gene suppressive information.
To further analyze MLL-39UTR, we dissected the 3 kb long
MLL-39UTR into consecutive smaller regions. Figure 3A shows
that the region between nucleotides (nt) 245–1143 constitutes the
smallest region conferring the highest repression, while the 1–245
region had a slight positive effect. Shorter fragments within the
245–1143 region had a significant but more moderate effect,
indicating that repression was not localized to one particular
sequence motif but rather was dispersed along the whole region. In
accordance, excising the 270—1140 region out of the entire MLL-
39UTR relieved the bulk of the repression effect (Fig. 3B),
indicating that most of the inhibitory effect on gene expression is
indeed localized to this ,900 bp region.
miRNAs are known to mediate repression of gene expression by
sequence specific interaction with 39UTRs to elicit induction of
mRNA instability and inhibition of protein translation [13,17,18].
Therefore, we examined whether they could be responsible for
MLL-39UTR suppression. Although no conserved miRNAs have
been predicted in the region (245–1143) nt of MLL-39UTR, we
assessed its effect on Renilla gene expression in HCT-116-Dicer
ex5
2/2(whichcontainsadeletioninexon5ofDicer,akeyplayerin
the generation of miRNAs [19]) compared with parental HCT-116
cells (Fig. 3C). No difference in Renilla activity was found between
these two cell lines (Fig. 3C), suggesting that miRNAs play a minor
role in this phenotype. To strengthen this result we evaluated the
effect of increasing MLL-39UTR levels on reporter expression and
compared it with the increase of p27-39UTR in a miR-221
expressing cell line [14], as it has been shown that miRNA activity
can be sequestered by artificially increasing the cellular amount of
target 39UTR mRNA [20]. While miR-221 effect over p27-39UTR
was saturated by target 39UTR level increase, MLL-39UTR
suppressive effect was only mildly reduced by the increase in
transfected reporter plasmid (Fig. 3D). Altogether, miRNAs seemed
unlikely to be responsible for MLL-39UTR-mediated repression.
Next, we investigated the mechanism of MLL-39UTR-mediated
gene repression by examining mRNA level and stability. We
transfected cells with Y2-empty or Y2-MLL-39UTR and examined
Renilla and Fireflyluciferase activity (proteinlevels) and mRNA levels.
Similar reduction in Renilla activity and Renilla mRNA levels in the
presence of MLL-39UTR were found with respect to normalizer
Firefly, suggesting that MLL-39UTR repression was mediated by
markedly reducing mRNA levels (Fig. 3E). We then measured the
stability of Renilla mRNA using actinomycin D (ActD), an inhibitor
of RNAPolymeraseII (RNAPII)[21]. While the Renilla mRNAlevel
was highly reduced when MLL-39UTR was present (Fig. 3E), its
stability remained high (Fig. 3F). We controlled ActD by measuring
the labile p27 mRNA (half life ,1 hour [22]. These results suggest
that MLL-39UTR may affect mRNA synthesis.
To examine the effect of MLL-39UTR on mRNA synthesis, we
either flipped MLL-39UTR 39-59 (Fig. 4A), or inserted a wt
polyadenylation signal and cleavage site (PAS), at position 245
(upstream of the repression region) of MLL-39UTR (Fig. 4B). 39end
sequencing analysis showed the expected cleavage and polyadenyl-
ation site triggered by this PAS (Supplementary Fig. S1D).
Interestingly, both manipulations resulted in complete abolishment
ofMLL-39UTRrepression.AscontrolsweusedamutantPAS(PAS-
MUT), and a PAS constructed in a reverse orientation (SAP), both
hardly affected MLL-39UTR repression (Fig. 4B). These results
indicate that MLL-39UTR influence transcription, only when it is
part of the transcribed unit. To directly examine this possibility, we
measured in vivo transcription rates of Renilla and control GAPDH
mRNAs using 4-thiouridine (4SU, [22], see materials and methods).
Figure 4C shows that MLL-39UTR had a major effect on
transcription rate, which was comparable to the reduction seen
with Renilla luciferase activity from the same experiment. Moreover,
the inclusion of a PAS prior to the repression region (same construct
presentedinFig. 4B) relievedmostoftranscription repression and,as
expected, Renilla luciferase activity.
We then hypothesize that RNA synthesis could be blocked by
RNA polymerase II (RNAPII) engaging and halting while
transcribing MLL-39UTR. To test this hypothesis, we IPed
RNAPII from U2OS cells and incubated beads with either
MLL-39UTR or the main PGs-39UTRs RNA probes. RNAPII IP
was verified by an immunoblot analysis (Fig. 4D) and IgG IP was
used to monitor specificity of RNAPII binding to 39UTRs.
Figure 4D shows a stronger retention of MLL-39UTR by RNAPII
(2 to 10 times) compared to the 39UTRs of the PGs. Therefore,
these results demonstrate an exclusively stronger RNAPII
interaction with MLL-39UTR that could correlate with a RNAPII
halt in transcription inside the 39UTR (Fig. 4E). To further
characterize this interaction we performed chromatin IPs (ChIPs)
with antibodies directed against phosphor-serine (pSer) 2, 5, or an
MLL-39UTR Gene Silencing
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RNAPII (general), and calculated enrichment values of the
phosphorylated forms over the general. We found that inclusion
of MLL-39UTR causes a sharp loss of pSer5, while pSer2
remained unchanged compared to AF-9-39UTR, which was used
as control (Fig. 4E). No difference was detected in the coding
sequence (CDS). While this result is correlative in its nature, it has
the potential to explain, at least in part, the gene expression
repressive effect of 39-UTR on MLL and the overexpression of
MLL-PG form upon MLL translocations.
Discussion
39UTRs are mainly viewed as regulators of mRNA stability and
translation through the binding of miRNAs or RNA-binding proteins
(RBPs). Here, we observed that 39UTRs could also influence gene
transcription. The 39UTR of MLL, when placed downstream of a
reporter gene, and when was part of the transcribed unit, led to a
dramatic reduction in gene expression levels. This effect did not map
to a particular motif, but it was rather smeared along a large region of
1 kb in MLL-39UTR. On the contrary, a similar pattern on reporter
gene expression was not observed with the 39UTRs of main MLL
partner genes (PGs). Interestingly, the repression mediated by MLL-
39UTR could be avoided by a preceding wt polyadenylation and
cleavage site (PAS), but not by a mutated PAS or by increasing the
copy number of 39UTR units in the cells. Furthermore, MLL-
39UTR, but not PGs-39UTRs, showed enhanced interaction with
RNAPII, suggesting a model by which the newly synthesized MLL-
39UTR RNA interferes with RNAPII progression (Fig. 4F). How
exactly this mRNA region affects RNAPII activity is not clear at the
moment. It is possible that, once synthesized, MLL-39UTR either
modifies RNAPII conformation to become a less efficient enzyme,
displace essential factors, or alternatively recruits RNA-binding
proteins that affect RNAPII activity. Alternatively, the MLL-39UTR
region may affect initiation of transcription. One hint we found is the
correlation of MLL-39UTR with a rapid loss of pSer5 from RNAPII-
CTD. How exactly this causes a ch a n g ei nR N A P I Ia c t i v i t y ,a n d
which factors are involved, remain to be elucidated. Nevertheless,
Figure 2. MLL-39UTR strongly inhibits gene expression. A, A schematic representation of MLL translocations at the mRNA level with putative
RBPs and miRNAs binding to MLL-39UTR and affecting gene expression. (PG). B, Transient transfection experiments in MCF-7 cells (MLL wt) using Y2,
a dual luciferase vector (Fig. S1), and pGL3 luciferase reporter constructs, with or without the human MLL-39UTR. Together with the pGL3 constructs,
we transfected pLR-SV40 (Renilla) as control. Relative Renilla and Firefly ratios are presented (R/F or F/R) as indicated. C, Y2 constructs, with or
without MLL-39UTR, were transiently transfected into the indicated cell lines and the relative R/F ratio was calculated. D, Transient transfection of Y2
reporter constructs containing the 39UTRs of MLL or its main PGs in HL-60 and Jurkat leukemic cell lines (both MLL wt). In the lower part a graphic
comparison of the different 39UTRs length. Coding region is depicted in grey and 39UTRs in black.
doi:10.1371/journal.pone.0025449.g002
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translocation could be an optimal way to assure a higher rate of N-
terminal MLL domains transcription, in the form of MLL-PG
mRNA. High expression of N-MLL would facilitate MLL-dimeriza-
tion and would promote leukemogenic transformation [23].
Materials and Methods
Cell lines and patient samples
Jurkat, HL-60, EOL-1, MV4-11, ML-2, MOLM13, NOMO1,
OCI-AML2 and THP-1 were cultured in RPMI1640 and U2OS,
HeLa, HEK293, MCF7, HCT116, and HCT116 Dicer ex52/2
in DMEM all supplemented with 10% fetal calf serum and
antibiotics. Cell lines were obtained from ATCC or DSMZ, except
HCT116 and HCT116 Dicer ex52/2 that were a kind gift of Dr.
Bert Vogelstein). Molecular characteristics of cell lines regarding
MLL are summarized in Table S1.
Patient samples were collected at the Department of Genetics,
University of Navarra, Spain. Leukemic blasts were obtained from
bone marrow (BM) of AML patients with more than 60% blasts.
The study has been approved by the Ethics Committee for
Research with Human Subjects and was carried out in accordance
Figure 4. The 39UTR of MLL inhibits mRNA synthesis. A and B, The indicated Y2 constructs were transfected to U2OS cells and Renilla and
Firefly luciferase was measured to calculate R/F ratios. PAS is the polyadenylation signal region of SV40 (PAS); PAS mutant (PAS-MUT) has four
nucleotide alterations in the PAS consensus motif; (SAP) is the PAS region in a reverse orientation (See Supplementary Material). All PAS regions were
cloned at position 245 of MLL-39UTR. C, U2OS cells were transfected with the indicated Y2 reporter constructs. Forty-eight hours later, 4-thiouridine
(4SU) was added and cells were incubated for 4 hours to mark newly transcribed RNA. Subsequently, RNA was isolated and the newly transcribed
mRNA was purified as described ([22], see material and methods). Relative levels of Renilla mRNA (to GAPDH) were determined and compared to
Renilla/Firefly luciferase activity extracted from the same cell population. D, RNAPII was IPed from U2OS cells and incubated with RNA probes
containing MLL (245–1143)-39UTR, or PG-39UTRs. Following incubation, beads were washed, RNA extracted and loaded on to a denaturing gel. Right
upper panel shows an immunoblot analysis with a RNAPII antibody. This experiment was repeated 3 times with a similar result. E, U2OS cells were
transfected with Y2-MLL-39UTR or Y2-AF9-39UTR and subjected to ChIP analysis with an antibody directed against the carboxy-ternminal region
(CTD) of RNAPII, and the CTD phosphor-specific antibodies phospho-S2 and S5. Bound Renilla (CDS) and 39UTR regions in the ChIP were detected by
PCR, and the enrichment of S2 and S5 compared to RNAPII in IPs is shown. F, A schematic representation of MLL-39UTR interaction with RNAPII and its
speculative effect on rate of transcription.
doi:10.1371/journal.pone.0025449.g004
Figure 3. Inhibition of gene expression by MLL-39UTR is at the mRNA level but largely independent of miRNAs and mRNA stability.
A and B, Several regions of MLL-39UTR, as depicted, were cloned downstream of Renilla in the Y2 vector, then transfected to U2OS cells and
luciferase activity was measured. The black thin lines represent deletion regions. C, Y2 constructs, with or without MLL-39UTR, were transiently
transfected into the indicated cell lines and Renilla activity relative to Firefly activity was measured. D, Transient transfection of increasing amounts of
Y2 empty, MLL-39UTR or p27-39UTR reporter constructs into U2OS cells. Relative R/F is presented. E, U2OS cells were transiently transfected with Y2
empty and MLL-39UTR. 48 h later cells were harvested and both luciferase activity as well as mRNA levels of Renilla and b-Actin were determined.
Presented are the relative R/F activity ratios and the Renilla/b-Actin mRNA ratios from the same cell population. F, U2OS cells were transiently
transfected with Y2 empty and MLL-39UTR reporter constructs. Forty eight hours later, actinomycin D (ActD) was added and cells were harvested at
the indicated time points thereafter. Then, RNA was extracted and levels of Renilla, b-Actin and p27 mRNAs were determined. Presented are the
Renilla and p27 mRNA levels relative to b-Actin and to time point 0.
doi:10.1371/journal.pone.0025449.g003
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molecular characteristics of the patients are summarized in Table
S2.
FISH analysis were performed as previously described [24]
using a dual color locus specific MLL probe (Vysis, Downers
Grove, IL).
Luciferase Constructs
For details see Data S1.
Luciferase Activity Analysis
For luciferase analysis, suspension cells were nucleofected
(amaxa technologies), while adherent cells were transfected using
Fugene. Dual luciferase-activity assays were performed 48 h after
transfection according to the manufacturer’s directions (Promega).
Results are represented as means and standard deviation (SD)
from three independent experiments.
qRT-PCR Analysis
Total RNA was extracted using TRIzol reagent (Life Technol-
ogies) according to the manufacturer’s instructions. Synthesis of
cDNA with Superscript III reverse transcriptase (Invitrogen) was
primed with oligo(dT). Primers (Data S1) were designed to amplify
150–200 bp fragments. Analyses were carried out using SYBR
Green PCR master mix (Applied Biosystems) and the ABI Prism
7000 system (Amersham-Pharmacia). The results were normalized
with respect to human b-actin. Ct values for gene expression were
calculated according to the Ct method.
Run-on
U2OS cells were transfected by means of Fugene with psi-
CHEk-2- empty, psi-CHECk-2- MLL-39UTR (1–1143) or the
same construct with the PAS at position 245. Forty hours later cells
were incubated with 500 uM 4-Thio-Uridine (4sU, Sigma) for
4 hr prior to RNA extraction by the Trizol method. Biotinylation
of 4sU-labeled RNA was performed using EZ-Link-Biotin-HPDP
(Pierce) dissolved in DMSO. Biotinylation of 100 ug total RNA
was carried out in 10 mM Tris (pH 7.4), 1 mM EDTA and
0.2 mg/ml Biotin-HPDP at a final RNA concentration of 100 ng/
ul for 1.5 h at room temperature. Unbound Biotin-HPDP was
efficiently removed by chloroform/isoamylalcohol (24:1) extrac-
tion. Afterward, RNA was precipitated by addition of a 0.1 volume
of 5 M NaCl and an equal volume of isopropanol, and then
washed with 70% ethanol. The RNA were resuspended in RNase-
free water and treated with DNase I for 1 h at 37uC and 65uC for
10 min to inactivate the enzyme and denaturate the RNA.
Denaturated RNA was then incubated with Dynabeads M-280
Streptavidin (Invitrogen) in rotation for 30 min at room
temperature. Beads were transferred and magnetically fixed to
columns. In the columns the beads were wash with washing buffer
(100 mM Tris pH 7.4, 10 mM EDTA, 1 M NaCl,0.1% Tween20)
and eluted by the addition of 100 mM dithiothreitol (DTT).
Biotinylated RNA was recovered by the eluted fraction using the
RNeasy Mini Elute Spin Columns (Qiagen) and was subjected to
cDNA synthesis with oligo(dT) and qRT-PCR analysis using
Renilla and GAPDH primers.
RNAPII IP and binding to RNA probes
U2OS cellswere lysed in immunoprecipitationbuffer (50 mM Tris
[pH 8.0], 150 mM NaCl, 1 mM NaF, 1% NP-40supplemented with
protease inhibitors). Lysates were centrifuged for 10 min at 13,0006
g and the supernatant was incubated for 1 hr with magnetic beads
(Invitrogen) coated with anti-RNA Polymerase II (Upstate). The
beads were washed four times with inmunoprecipitation buffer and
two times with RNA binding buffer (50 mM Tris-HCl [pH 8.0],
10% glycerol, 0.2 mg/ml BSA, 0.01% NP-40, 0.5 mM DTT,
100 mM KCl, 2 mM MgCl2). After the last wash, the beads were
resuspended in 200 ml of RNA binding buffer and incubated with
15,000 cpm of radiolabeled in vitro transcribed RNA (Ambion) for
15 min at room temperature. The beads were washed three times
with RNA binding buffer. Beads were suspended in 20 mlo fw a t e r
with 1% SDS and 200 mg/ml of Proteinase K and incubated for
30 min at 50 C. The whole volume was applied to a denaturing
polyacrylamide gel (3%). The radioactive retained RNA was
quantified using a Fuji Phosphoimager BAS 100.
ChIP
U2OS cells were transfected with either 100 ng of Y2-MLL-
39UTR or 100 ng of Y2-AF9-39UTR and grown in DMEM (10%
FCS) for 48 hours, crosslinked with 1% formaledehyde for
10 minutes and the crosslinking was stopped with 0.125 M glycine
for 5 minutes at room temperature. Cells were then washed with ice
cold 16PBS. Cell pellets were resuspended and incubated in cell
lysis buffer (50 mM Tris-HCl [pH 8.0], 85 mM KCl, 0.5% NP40,
and protease inhibitor (Roche)) for 10 minutes. Nuclear pellets were
spun down at 5,000 rpm for 5 minutes, resuspended in nuclear lysis
buffer (1% SDS, 10 mM EDTA, 50 mM Tris?HCl (pH 8.0)), and
incubated for another 10 minutes. Chromatin was sonicated for
30 minutes, with pulses every 30 seconds and then centrifuged at
14,000 rpm for 10 minutes to removethe debris. 5 mg of anti-RNA
Polymerase II (Millipore), anti pSer2-Polymerase II, or anti pSer5-
polymerase II (Covance) was added to the lysates and incubated at
4uC overnight. 40 mg of agarose protein A was added and
incubated for 1 hour at 4uC. Beads were washed 5 times. The
DNA complexes were eluted and reverse crosslinked in 0.3 M NaCl
at 65uC for 4 hours. Protein was digested withproteinase K at 45uC
for 1 hour and the DNA was purified with Qiagen PCR columns.
To show differential enrichment of phosphorilated forms of RNA
Polymerase II to either Renilla CDS or MLL and AF9 39UTR, the
purified DNA was amplified with following primers:
Renilla Forward CGGAAACTGGAGCCTGAGGA
Renilla Reverse AACCCAGGGTCGGACTCGAT
MLL 39UTR Forward ATGGGGTCCCTAGCAGACTT
MLL 39UTR Reverse TTCGACAGACGCTGTAGGTG
AF9 39UTR Forward GACAGCTCAACAATGCTGGA
AF9 39UTR Reverse GGACCAAATAGCCACCTTGA
P7-T25N CAAGCAGAAGACGGCATACGAGATTTTTT-
TTTTTTTTTTTTTTTTTTTVN
P7 CAAGCAGAAGACGGCATACGAGAT
A written consent was obtained from all participants involved in
this study.
Supporting Information
Data S1 Raw Ct for AF9 mRNA levels quantification with the
59and 39pairs, respectively. B, Oligos used for constructs making,
indicating length and restriction enzymes used. C, Oligos sed for
quantitative Real-Time PCR of the indicated genes.
(PDF)
Figure S1 A, a schematic drawing of the psiCHECK reporter
vector backbone used in this study. B, transient transfection of
psiCHECK reporter constructs containing human and mouse
MLL-39UTRs in MCF-7 cells. C, transient transfection of
psiCHECK reporter constructs containing MLL and main PG
39UTRs. D, Cells were transfected with Y2-PAS-MLL-39UTR
and 39end analysis was performed using RT with a P7-T25N oligo
and PCR with P7 and a sequence specific primer. Sequence
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Table S1 Main clinical and molecular characteristics of cells
lines used in MLL-PG and PG-MLL mRNA levels evaluation.
MLL-PTD means MLL partial tandem duplication, AML-M2,
AML-M4 and MLL-M5 refer to different subtypes of AML
according to the French-American British (FAB) classification. T-
ALL refers to T cell lynphocytic leukemia.
(DOCX)
Table S2 Main clinical and molecular characteristics of patient
samples are shown. Sex (M means male; F means female), AML-
M2, AML-M4 and MLL-M5 refer to different subtypes of AML
according to the French-American British (FAB) classification.
ALL refers to acute lymphocytic leukemia and MDS to
myelodysplastic syndrome.
(DOCX)
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